SEC Filings

Form 10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 11/07/2017
Document Outline
Entire Document (1993.1 KB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - CAUTIONARY NOTE FORWARD-LOOKING STATEMENTS
Page 4 - N/A
Page 5 - PART I FINANCIAL INFORMATION
Page 6 - Proteon Therapeutics, Inc.
Page 7 - Proteon Therapeutics, Inc.
Page 8 - Proteon Therapeutics, Inc.
Page 9 - Fair Value of Financial Instruments
Page 10 - Recent Accounting Pronouncements
Page 11 - Restricted cash related to facilities leases
Page 12 - Stock Options
Page 13 - N/A
Page 14 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 15 - Recent Developments
Page 16 - General and Administrative Expenses
Page 17 - Derivative Financial Instruments
Page 18 - Research and Development Expenses
Page 19 - General and Administrative Expenses.
Page 20 - Cash Flows
Page 21 - Contractual Obligations
Page 22 - Changes in Internal Control Over Financial Reporting
Page 23 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 24 - We have never generated any revenue from product sales and may never be profitable.
Page 25 - Risks Related to Clinical Development, Regulatory Review and Approval of Our Product
Page 26 - If clinical trials of vonapanitase or any additional product candidates fail to demonstrate safety a
Page 27 - We may be unable to obtain regulatory approval for vonapanitase or any additional product candidates
Page 28 - We may face difficulty in enrolling patients for clinical trials.
Page 29 - If we experience any of a number of possible unforeseen events in connection with clinical trials of
Page 30 - Any product for which we obtain FDA approval will be subject to extensive ongoing regulatory require
Page 31 - Vonapanitase may cause undesirable side effects or have other properties that could delay or prevent
Page 32 - A breakthrough therapy, fast track product, priority review, or other designation by the FDA for our
Page 33 - Advertising and promotion of any product candidate that obtains approval in the United States will b
Page 34 - We may not be able to comply with requirements of foreign jurisdictions in conducting trials outside
Page 35 - Even if vonapanitase or any additional product candidates receive regulatory approval, they may fail
Page 36 - Vonapanitase, or any additional product candidates for which we seek approval as biologic products,
Page 37 - If the government or other third-party payors fail to provide adequate and timely coverage and payme
Page 38 - Currency fluctuations in the Swiss Franc and changes in exchange rates could adversely affect our bu
Page 39 - We rely on third parties to conduct, supervise and monitor our clinical trials. If these third parti
Page 40 - We may seek to form partnerships in the future with respect to vonapanitase or any additional produc
Page 41 - Risks Related to Our Intellectual Property
Page 42 - Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure
Page 43 - If we are unable to adequately protect our proprietary technology, or obtain and maintain issued pat
Page 44 - ex parte
Page 45 - We may be subject to claims challenging the inventorship or ownership of our patents and other intel
Page 46 - Some of our intellectual property may have been discovered through government funded programs and th
Page 47 - Changes in United States patent law could diminish the value of patents in general, thereby impairin
Page 48 - Numerous factors may limit any potential competitive advantage provided by our intellectual property
Page 49 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 50 - If we engage in acquisitions in the future, we will incur a variety of costs and we may never realiz
Page 51 - Our business and operations would suffer in the event of system failures or security breaches.
Page 52 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 53 - Risks Related to Our Common Stock
Page 54 - Actual or potential sales of our Common Stock by our employees, including our executive officers, pu
Page 55 - Our issuance of Common Stock under our At-The-Market offering program may be dilutive, and there may
Page 56 - Raising additional funds through debt or equity financing could be dilutive and may cause the market
Page 57 - We will incur significant increased costs as a result of operating as a public company, and our mana
Page 58 - We could be subject to securities class action litigation.
Page 59 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Page 60 - SIGNATURES
Page 61 - EXHIBIT INDEX
Subdocument 2 - EX-10.2 - EXHIBIT 10.2
Page 1 - Exhibit 10.2
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - EXHIBIT A
Page 9 - N/A
Page 10 - EXHIBIT B
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - Outside Completion Date
Page 15 - EXHIBIT C
Page 16 - DELINEATION OF TENANT IMPROVEMENT TURN-KEY SCOPE
Page 17 - DELINEATION OF TENANT IMPROVEMENT TURN-KEY SCOPE
Page 18 - DELINEATION OF TENANT IMPROVEMENT TURN-KEY SCOPE
Page 19 - EXHIBIT D
Page 20 - N/A
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer